SCHEMBL6788717

SCHEMBL6788717

CC(=O)c1ccc(-c2ccccc2C(=O)Nc2ccc(N(CCc3ccccn3)C(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SMO Q99835 2/20 0.41
TRPV1 Q8NER1 2/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 1/20 0.37
SYK P43405 4/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
AURKB Q96GD4 1/20 0.36
INCENP Q9NQS7 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793636 0.93 SMO (0.42) SMN1; SMN2SMOTRPV1LMNAHTT
SCHEMBL6792911 0.93 SMO (0.47) SMOLMNAHTTPOLBGAA
SCHEMBL6795007 0.92 SMO (0.48) SMOLMNAHTTPOLBGAA
SCHEMBL6799630 0.92 SMO (0.42) SMN1; SMN2SMOLMNAHTTPOLB
SCHEMBL6793251 0.92 SMO (0.42) SMOTRPV1LMNAHTTPOLB
SCHEMBL6791610 0.92 SMO (0.42) MAPTSMN1; SMN2SMOLMNAHTT
SCHEMBL6800714 0.91 SMO (0.42) SMN1; SMN2SMOTRPV1LMNAHTT
SCHEMBL6788937 0.91 SMO (0.42) SMOTRPV1LMNAHTTPOLB
SCHEMBL6788159 0.91 SMO (0.43) MAPTSMN1; SMN2SMOLMNAHTT
SCHEMBL6795221 0.91 CNR1 (0.43) SMN1; SMN2SMOLMNAHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 MAPT 4795/4885SMN1; SMN2 2504/4885SMO 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.